Noxafil



Indications and Reactions:

Role Indications Reactions
Primary
Drug Use For Unknown Indication 17.8%
Product Used For Unknown Indication 16.8%
Prophylaxis 12.0%
Fungal Infection 9.0%
Aspergillosis 8.3%
Antifungal Prophylaxis 7.5%
Bronchopulmonary Aspergillosis 6.0%
Zygomycosis 4.3%
Acute Myeloid Leukaemia 3.2%
Chemotherapy 2.5%
Fusarium Infection 1.7%
Graft Versus Host Disease 1.7%
Pyrexia 1.7%
Antifungal Treatment 1.3%
Chronic Granulomatous Disease 1.3%
Lung Infection 1.2%
Haematological Malignancy 1.0%
Mucormycosis 1.0%
Pneumonia Fungal 1.0%
Sinusitis Fungal 1.0%
Death 11.8%
Drug Ineffective 7.6%
Sepsis 7.6%
Vomiting 7.6%
Fusarium Infection 4.9%
Liver Function Test Abnormal 4.9%
Pancreatitis 4.9%
Rash 4.9%
Drug Interaction 4.2%
Myalgia 4.2%
Neutropenia 4.2%
Pancytopenia 4.2%
Respiratory Failure 4.2%
Septic Shock 4.2%
Thrombocytopenia 4.2%
Aspergillosis 3.5%
Congestive Cardiomyopathy 3.5%
Paraesthesia 3.5%
Polyneuropathy 3.5%
Arrhythmia 2.8%
Secondary
Product Used For Unknown Indication 68.6%
Drug Use For Unknown Indication 5.9%
Prophylaxis 5.3%
Acute Myeloid Leukaemia 4.8%
Aspergillosis 2.1%
Hepatosplenic Candidiasis 1.6%
Zygomycosis 1.3%
Cytomegalovirus Infection 1.2%
Graft Versus Host Disease 1.2%
Fungal Infection 1.1%
Gastrointestinal Candidiasis 1.1%
Extravasation 1.0%
Antifungal Prophylaxis 0.7%
Atypical Mycobacterial Infection 0.7%
Leukaemia 0.7%
Gastrooesophageal Reflux Disease 0.6%
Hypertension 0.6%
Acute Leukaemia In Remission 0.5%
Acute Promyelocytic Leukaemia 0.5%
Aplasia 0.5%
Toxic Epidermal Necrolysis 17.8%
Sinoatrial Block 8.2%
Renal Failure Acute 6.8%
Cytolytic Hepatitis 5.5%
Myositis 5.5%
Overdose 5.5%
Renal Disorder 5.5%
Venous Stent Insertion 5.5%
Bone Marrow Failure 4.1%
Condition Aggravated 4.1%
Drug Interaction 4.1%
Pulmonary Oedema 4.1%
Tinnitus 4.1%
Arrhythmia 2.7%
Aspergillosis 2.7%
Epilepsy 2.7%
General Physical Health Deterioration 2.7%
Hyperbilirubinaemia 2.7%
Jaundice 2.7%
Necrotising Ulcerative Gingivostomatitis 2.7%
Concomitant
Product Used For Unknown Indication 28.2%
Drug Use For Unknown Indication 13.7%
Prophylaxis 11.3%
Acute Myeloid Leukaemia 10.5%
Acute Lymphocytic Leukaemia 5.3%
Nausea 3.4%
Hypertension 3.3%
Antifungal Prophylaxis 2.9%
Chronic Graft Versus Host Disease 2.8%
Pain 2.7%
Prophylaxis Against Graft Versus Host Disease 2.2%
Antiviral Prophylaxis 1.7%
Bone Marrow Conditioning Regimen 1.6%
Infection 1.6%
Infection Prophylaxis 1.6%
Diabetes Mellitus 1.6%
Febrile Neutropenia 1.5%
Constipation 1.4%
Pneumonia 1.4%
Anxiety 1.3%
Sepsis 10.7%
Death 7.1%
Pyrexia 7.1%
Toxic Encephalopathy 7.1%
Staphylococcal Infection 6.0%
Vomiting 6.0%
Platelet Count Decreased 4.8%
Pneumonia 4.8%
Renal Failure Acute 4.8%
Thrombocytopenia 4.8%
Thrombotic Thrombocytopenic Purpura 4.8%
Acute Pulmonary Oedema 3.6%
Anaemia 3.6%
Hypertension 3.6%
Joint Swelling 3.6%
Nausea 3.6%
Nephrogenic Diabetes Insipidus 3.6%
Neutropenic Colitis 3.6%
Neutropenic Sepsis 3.6%
Pharyngolaryngeal Pain 3.6%
Interacting
Hepatosplenic Candidiasis 14.6%
Zygomycosis 14.0%
Product Used For Unknown Indication 12.1%
Bone Marrow Failure 10.8%
Convulsion Prophylaxis 5.7%
Drug Use For Unknown Indication 5.7%
Prophylaxis 5.7%
Chronic Myeloid Leukaemia 4.5%
Acute Myeloid Leukaemia 3.8%
Acute Promyelocytic Leukaemia 3.8%
Chronic Myeloid Leukaemia Transformation 3.2%
Lung Transplant 3.2%
Bronchopulmonary Aspergillosis 2.5%
Transient Psychosis 2.5%
Acute Leukaemia In Remission 1.3%
Agitation 1.3%
Antifungal Prophylaxis 1.3%
Atrial Fibrillation 1.3%
Breast Cancer 1.3%
Hepatic Candidiasis 1.3%
Drug Interaction 25.7%
Vomiting 11.4%
Sinoatrial Block 7.1%
Tremor 7.1%
Atrioventricular Block Second Degree 5.7%
Malabsorption 4.3%
Mesenteric Vein Thrombosis 4.3%
Prescribed Overdose 4.3%
Pulmonary Haemosiderosis 4.3%
Sinus Tachycardia 4.3%
Arrhythmia 2.9%
Hypertriglyceridaemia 2.9%
Metastases To Central Nervous System 2.9%
Myocardial Infarction 2.9%
Sinus Bradycardia 2.9%
Bradycardia 1.4%
Myositis 1.4%
Pericardial Effusion 1.4%
Psychotic Disorder 1.4%
Pulmonary Haemorrhage 1.4%